Butyltolylquinuclidine

2-Butyl-3-(p-tolyl)quinuclidine (BTQ) is a stimulant DRI.[1] It is one of a number of substituted quinuclidine derivatives developed as potential medications for the treatment of cocaine abuse,[2] and produces similar effects to cocaine in animal studies, although milder and longer-lasting.

Butyltolylquinuclidine
Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: legal
Identifiers
IUPAC name
  • (2R,3S,4S)-2-butyl-3-p-tolylquinuclidine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H27N
Molar mass257.421 g·mol−1
3D model (JSmol)
SMILES
  • C3CC1CCN3C(CCCC)C1c(cc2)ccc2C
InChI
  • InChI=1S/C18H27N/c1-3-4-5-17-18(15-8-6-14(2)7-9-15)16-10-12-19(17)13-11-16/h6-9,16-18H,3-5,10-13H2,1-2H3
  • Key:QYIZEJQSBLRXJK-UHFFFAOYSA-N
  (verify)

See also

References
  1. Sakamuri S, Enyedy IJ, Zaman WA, Tella SR, Kozikowski AP, Flippen-Anderson JL, et al. (March 2003). "2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors". Bioorganic & Medicinal Chemistry. 11 (6): 1123–36. doi:10.1016/S0968-0896(02)00450-9. PMID 12614900.
  2. Enyedy IJ, Sakamuri S, Zaman WA, Johnson KM, Wang S (February 2003). "Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors". Bioorganic & Medicinal Chemistry Letters. 13 (3): 513–7. doi:10.1016/S0960-894X(02)00943-5. PMID 12565962.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.